AR049940A1 - Uso de compuestos peptidicos para tratar tremor esencial y otros sindromes de tremor - Google Patents

Uso de compuestos peptidicos para tratar tremor esencial y otros sindromes de tremor

Info

Publication number
AR049940A1
AR049940A1 ARP050102604A ARP050102604A AR049940A1 AR 049940 A1 AR049940 A1 AR 049940A1 AR P050102604 A ARP050102604 A AR P050102604A AR P050102604 A ARP050102604 A AR P050102604A AR 049940 A1 AR049940 A1 AR 049940A1
Authority
AR
Argentina
Prior art keywords
azethyl
lower alkyl
heterocyclyl
aryl
group
Prior art date
Application number
ARP050102604A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Stoehr
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of AR049940A1 publication Critical patent/AR049940A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/03Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP050102604A 2004-06-24 2005-06-24 Uso de compuestos peptidicos para tratar tremor esencial y otros sindromes de tremor AR049940A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58208404P 2004-06-24 2004-06-24

Publications (1)

Publication Number Publication Date
AR049940A1 true AR049940A1 (es) 2006-09-13

Family

ID=34970895

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102604A AR049940A1 (es) 2004-06-24 2005-06-24 Uso de compuestos peptidicos para tratar tremor esencial y otros sindromes de tremor

Country Status (19)

Country Link
US (1) US7427601B2 (cg-RX-API-DMAC7.html)
EP (1) EP1758606A1 (cg-RX-API-DMAC7.html)
JP (1) JP5038892B2 (cg-RX-API-DMAC7.html)
KR (1) KR20070034477A (cg-RX-API-DMAC7.html)
CN (1) CN1964733B (cg-RX-API-DMAC7.html)
AR (1) AR049940A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005256468B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0512622A (cg-RX-API-DMAC7.html)
CA (1) CA2566301C (cg-RX-API-DMAC7.html)
EA (1) EA013592B1 (cg-RX-API-DMAC7.html)
IL (1) IL179732A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06015010A (cg-RX-API-DMAC7.html)
MY (1) MY146509A (cg-RX-API-DMAC7.html)
NO (1) NO20070423L (cg-RX-API-DMAC7.html)
NZ (1) NZ551207A (cg-RX-API-DMAC7.html)
TW (1) TWI361693B (cg-RX-API-DMAC7.html)
UA (1) UA88166C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006000397A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200609021B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60120104T2 (de) * 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
PT1243263E (pt) * 2001-03-21 2003-03-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma
ATE428413T1 (de) * 2003-12-02 2009-05-15 Sanol Arznei Schwarz Gmbh Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
CA2562937A1 (en) * 2004-04-16 2005-10-27 Schwarz Pharma Ag Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604655A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
NZ552651A (en) * 2004-08-27 2010-07-30 Sanol Arznei Schwarz Gmbh Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
US7902401B2 (en) * 2006-12-14 2011-03-08 Nps Pharmaceuticals, Inc. Fluorinated compounds
TWI397417B (zh) 2006-06-15 2013-06-01 Ucb Pharma Gmbh 具有協同抗驚厥功效之醫藥組成物
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
US8450336B2 (en) * 2006-12-14 2013-05-28 Nps Pharmaceuticals, Inc Use of D-serine derivatives for the treatment of anxiety disorders
US7747551B2 (en) * 2007-02-21 2010-06-29 Neurovista Corporation Reduction of classification error rates and monitoring system using an artificial class
WO2011037833A2 (en) 2009-09-23 2011-03-31 The University Of North Carolina At Chapel Hill Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
US20110281808A1 (en) * 2010-05-14 2011-11-17 Allmax Nutrition Inc. Composition and Method for Increasing Pre Workout Thermogenics
JP6027539B2 (ja) 2010-12-02 2016-11-16 ウーツェーベー ファルマ ゲーエムベーハーUcb Pharma Gmbh ラコサミドの1日1回投与用製剤
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
KR20230050474A (ko) * 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378729A (en) 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
US6589994B1 (en) 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
CA2418455A1 (en) * 2000-08-17 2002-02-21 Teva Pharmaceutical Industries, Ltd. Valproic acid derivatives for the treatment of pain
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
ES2348646T3 (es) 2000-08-25 2010-12-10 Research Corporation Technologies, Inc. Aminoacidos anticonvulsionantes para el tratamiento de la neurosis obsesivo-compulsiva.
ATE397584T1 (de) 2000-11-21 2008-06-15 Ucb Pharma Sa N-alkylierte gaba verbindungen, verfahren zu deren herstellung und deren verwendung als arzneimittel
CA2438930A1 (en) * 2001-02-23 2002-09-06 Johns Hopkins University Treatment of tics, tremors and related disorders
DE60120104T2 (de) 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
PT1243263E (pt) 2001-03-21 2003-03-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6828462B2 (en) * 2001-11-07 2004-12-07 Merz Pharma Gmbh & Co. Kgaa Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
WO2004024096A2 (en) * 2002-09-13 2004-03-25 Eisai Co., Ltd. Method of treating tremors
ATE384078T1 (de) 2002-11-18 2008-02-15 Bioprospecting Nb Inc Paralytisches peptide von der spitzmaus sowie dessen nutzung in der therapie von neuromuskulären krankheiten
US20050227961A1 (en) 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
EP1604654A1 (en) 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604656A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)

Also Published As

Publication number Publication date
US7427601B2 (en) 2008-09-23
JP2008503533A (ja) 2008-02-07
EP1758606A1 (en) 2007-03-07
EA013592B1 (ru) 2010-06-30
AU2005256468A1 (en) 2006-01-05
UA88166C2 (ru) 2009-09-25
AU2005256468B2 (en) 2010-12-09
MXPA06015010A (es) 2007-03-26
NO20070423L (no) 2007-03-22
TW200603823A (en) 2006-02-01
CN1964733B (zh) 2012-05-23
CA2566301A1 (en) 2006-01-05
US20050288234A1 (en) 2005-12-29
TWI361693B (en) 2012-04-11
CA2566301C (en) 2011-06-14
BRPI0512622A (pt) 2008-03-25
JP5038892B2 (ja) 2012-10-03
IL179732A0 (en) 2007-05-15
MY146509A (en) 2012-08-15
NZ551207A (en) 2010-07-30
ZA200609021B (en) 2008-04-30
CN1964733A (zh) 2007-05-16
EA200700108A1 (ru) 2007-06-29
WO2006000397A1 (en) 2006-01-05
KR20070034477A (ko) 2007-03-28

Similar Documents

Publication Publication Date Title
AR049940A1 (es) Uso de compuestos peptidicos para tratar tremor esencial y otros sindromes de tremor
AR056467A1 (es) USO DE COMPUESTOS PEPTíDICOS PARA TRATAR DOLOR MUSCULAR
AR061475A1 (es) Compuestos peptidicos para tratar status epilepticus refractario
AR061743A1 (es) Compuestos peptidicos para el tratamiento de trastornos de hiperexcitabilidad y trastornos asociados con disfuncion del canal de hierro
AR061476A1 (es) Composicion farmaceutica con efecto anticonvulsivo sinergico
AR050612A1 (es) Novedoso uso de compuestos peptidos para tratar dolor por cancer de huesos, dolor inducido por quimioterapia y nucleosidos y composicion farmaceutica
AR112414A1 (es) Agonistas del receptor tipo toll 7 (tlr7) que tienen una porción benzotriazol, conjugados de estos y métodos y usos de estos
AR112689A1 (es) Agonistas del receptor tipo toll 7 (tlr7) que tienen porciones aromáticas ligadas al heteroátomo, conjugados de estos y métodos y usos de estos
PA8456901A1 (es) 2-aminopiridinas que contienen sustituyentes de anillos condensados
Leclercq et al. Genetic background of mice strongly influences treatment resistance in the 6 Hz seizure model
CY1119435T1 (el) Σκευασμα για αντισωμα εναντι- αλφα4βητα7
AR050970A1 (es) Pirimidinas 5-sustituidas con carbociclos o heterociclos inhibidoras del vih; composiciones farmaceuticas que las contienen y uso de las mismas como medicamentos.
AR100770A1 (es) Uso de oxadiazoles sustituidos para combatir hongos fitopatogénicos
PE20071020A1 (es) Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa
DE602007010781D1 (de) N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid-derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration
MX2018010852A (es) Metodos para tratar la depresion con antagonistas del receptor de orexina-2.
AR029185A1 (es) Derivado de naftiridina
Luksik et al. The role of immune checkpoint inhibition in the treatment of brain tumors
AR085285A1 (es) Metodos para tratar enfermedades de la retina
CY1125225T1 (el) 6-μελεις αζα-ετεροκυκλοι που περιεχουν eνωσεις τροποποιησης υποδοχεα δελτα-οπιοειδων, μεθοδοι χρησης και δημιουργιας αυτων
EA201690719A1 (ru) Композиции гербицидов и защитных средств, содержащие амиды n-(1,3,4-оксадиазол-2-ил)арилкарбоновой кислоты
TR200103351T2 (tr) Nos inhibitörleri için yeni farmasötik kombinasyonlar.
AR050098A1 (es) Uso de compuestos peptidicos para tratar dolor en la neuralgia trigeminal
CO2019011969A2 (es) Compuesto de n-(4-piridil)nicotinamida o sal del mismo
AR050096A1 (es) Uso de compuestos peptidicos para tratar disquinesia

Legal Events

Date Code Title Description
FA Abandonment or withdrawal